Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’s top growth stock picks. On February 18, Eli Lilly and Company (NYSE:LLY) said using Taltz (ixekizumab) together with Zepbound (tirzepatide) worked better than Taltz alone in adults who had moderate-to-severe plaque psoriasis and also had obesity or were overweight. Eli Lilly (LLY) Expands Pipeline With Positive Trial Data and New Licensing Deal Eli Lilly said the results came from its Phase 3b TOGETHER-PsO study, which tested Taltz alone vs. Talt ...

Group 1: Clinical Trial Results - Eli Lilly's TOGETHER-PsO trial showed that 27.1% of participants receiving Taltz and Zepbound achieved complete skin clearance and at least 10% weight loss, compared to 5.8% for Taltz alone, meeting the primary endpoint [2] - The combination of Taltz and Zepbound resulted in a 40% relative increase in the proportion of patients achieving PASI 100 compared to Taltz monotherapy (40.6% vs. 29%) [2] Group 2: Licensing Agreement - CSL Limited entered into an exclusive licensing agreement with Eli Lilly for the development and commercialization of clazakizumab, with an upfront payment of $100 million and potential milestone payments and royalties on global net sales [4] - CSL retains exclusive rights to develop clazakizumab for preventing cardiovascular events in patients with end-stage kidney disease, while Lilly will explore additional indications [5] Group 3: Stock Performance - The stock is currently trading 2.7% below its 20-day simple moving average and 3.2% below its 50-day simple moving average, indicating short-term weakness, but remains 4.3% above its 100-day simple moving average and 17.6% above its 200-day simple moving average, suggesting longer-term strength [7] - The RSI is at 48.22, indicating neutral territory, while the MACD shows bearish pressure with a value of -5.0984 below its signal line of -3.9365 [8]

Eli Lilly and Company (NYSE:LLY) is included among the 16 Best Dividend Stocks with Rising Payouts. Eli Lilly (LLY) Expands Pipeline with Clazakizumab Agreement, Reuters Reports According to a Reuters report on February 18, Australia’s CSL said it had granted Eli Lilly and Company (NYSE:LLY) certain rights to develop and commercialize clazakizumab, an anti-interleukin-6 monoclonal antibody. In return, CSL will receive an upfront payment of $100 million. CSL will keep exclusive rights to develop and comme ...

Core Viewpoint - Australia's CSL has entered into an exclusive licensing agreement with Eli Lilly and Co, allowing CSL to develop and commercialize clazakizumab, an antibody targeting specific medical conditions [1] Group 1: Licensing Agreement - The agreement grants CSL certain rights related to the development and commercialization of clazakizumab [1] - This partnership is expected to enhance CSL's portfolio in the biopharmaceutical sector [1] Group 2: Product Focus - Clazakizumab is an antibody aimed at treating specific medical conditions, indicating a focus on innovative therapies [1] - The collaboration with Eli Lilly highlights CSL's commitment to expanding its therapeutic offerings [1]